TY - JOUR
T1 - Progenitor B-1 B-cell acute lymphoblastic leukemia is associated with collaborative mutations in 3 critical pathways
AU - Gough, Sheryl M.
AU - Goldberg, Liat
AU - Pineda, Marbin
AU - Walker, Robert L.
AU - Zhu, Yuelin J.
AU - Bilke, Sven
AU - Chung, Yang Jo
AU - Dufraine, Joseph
AU - Kundu, Subhadip
AU - Jacoby, Elad
AU - Fry, Terry J.
AU - Fischer, Susanna
AU - Panzer-Grümayer, Renate
AU - Meltzer, Paul S.
AU - Aplan, Peter D.
N1 - Publisher Copyright:
© 2017 American Society of Hematology. All rights reserved.
PY - 2017/9/12
Y1 - 2017/9/12
N2 - B-1 and B-2 lymphocytes are derived from distinct developmental pathways and represent layered arms of the innate and adaptive immune systems, respectively. In contrast to a majority of murine B-cell malignancies, which stain positive with the B220 antibody, we discovered a novel form of B-cell leukemia in NUP98-PHF23 (NP23) transgenic mice. The immunophenotype (Lin2 B2202 CD191 AA4.11) was identical to that of progenitor (pro) B-1 cells, and VH gene usage was skewed toward 39 V regions, similar to murine fetal liver B cells. Moreover, the gene expression profile of these leukemias was most similar to that of fetal liver pro-B fraction BC, a known source of B-1 B cells, further supporting a pro–B-1 origin of these leukemias. The NP23 pro–B-1 acute lymphoblastic leukemias (ALLs) acquired spontaneous mutations in both Bcor and Janus kinase (Jak) pathway (Jak1/2/3 and Stat5a) genes, supporting a hypothesis that mutations in 3 critical pathways (stem-cell self-renewal, B-cell differentiation, and cytokine signaling) collaborate to induce B-cell precursor (BCP) ALL. Finally, the thymic stromal lymphopoietin (Tslp) cytokine is required for murine B-1 development, and chromosomal rearrangements resulting in overexpression of the TSLP receptor (CRLF2) are present in some patients with high-risk BCP-ALL (referred to as CRLF2r ALL). Gene expression profiles of NP23 pro–B-1 ALL were more similar to that of CRLF2r ALL than non-CRLF2r ALL, and analysis of VH gene usage from patients with CRLF2r ALL demonstrated preferential usage of VH regions used by human B-1 B cells, leading to the suggestion that this subset of patients with BCP-ALL has a malignancy of B-1, rather than B-2, B-cell origin.
AB - B-1 and B-2 lymphocytes are derived from distinct developmental pathways and represent layered arms of the innate and adaptive immune systems, respectively. In contrast to a majority of murine B-cell malignancies, which stain positive with the B220 antibody, we discovered a novel form of B-cell leukemia in NUP98-PHF23 (NP23) transgenic mice. The immunophenotype (Lin2 B2202 CD191 AA4.11) was identical to that of progenitor (pro) B-1 cells, and VH gene usage was skewed toward 39 V regions, similar to murine fetal liver B cells. Moreover, the gene expression profile of these leukemias was most similar to that of fetal liver pro-B fraction BC, a known source of B-1 B cells, further supporting a pro–B-1 origin of these leukemias. The NP23 pro–B-1 acute lymphoblastic leukemias (ALLs) acquired spontaneous mutations in both Bcor and Janus kinase (Jak) pathway (Jak1/2/3 and Stat5a) genes, supporting a hypothesis that mutations in 3 critical pathways (stem-cell self-renewal, B-cell differentiation, and cytokine signaling) collaborate to induce B-cell precursor (BCP) ALL. Finally, the thymic stromal lymphopoietin (Tslp) cytokine is required for murine B-1 development, and chromosomal rearrangements resulting in overexpression of the TSLP receptor (CRLF2) are present in some patients with high-risk BCP-ALL (referred to as CRLF2r ALL). Gene expression profiles of NP23 pro–B-1 ALL were more similar to that of CRLF2r ALL than non-CRLF2r ALL, and analysis of VH gene usage from patients with CRLF2r ALL demonstrated preferential usage of VH regions used by human B-1 B cells, leading to the suggestion that this subset of patients with BCP-ALL has a malignancy of B-1, rather than B-2, B-cell origin.
UR - http://www.scopus.com/inward/record.url?scp=85067214084&partnerID=8YFLogxK
U2 - 10.1182/bloodadvances.2017009837
DO - 10.1182/bloodadvances.2017009837
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
AN - SCOPUS:85067214084
SN - 2473-9529
VL - 1
SP - 1749
EP - 1759
JO - Blood advances
JF - Blood advances
IS - 20
ER -